Link here. BIRMINGHAM, United Kingdom –‐ April 3, 2014 – Nexvet Biopharma, a leading veterinary biologic drug developer, today announced that its Chief Scientific Officer, Professor David Gearing, will be presenting at the British Small Animal Veterinary Association (BSAVA) Congress 2014. The BSAVA Congress runs from April 3 – 6 and is one of Europe’s largest […]
SEA:NZX MARKET UPDATE 1 April 2014 SeaDragon Investor Update March 2014 (Link here). SeaDragon, Australasia’s largest refiner and blender of high-quality, internationally certified concentrated fish oils and fractions, including Omega-3 oils, today releases its investor update. The update includes: • an update on trading; • significant growth in squalene business following the execution of a raw […]
10 March 2014. Link here. SeaDragon signs significant raw material supply contract Agreement overcomes historical supply constraints Australasia’s largest fish-oil refiner SeaDragon (NZX: SEA) announces a new raw material supply agreement has been signed that will underpin its Nelson-based squalene manufacturing operations, and enable the business to seek new market opportunities in the pharmaceutical and cosmetic […]
ASX Announcement (link here). 28 February 2014.
February 26, 2014. Link here. Cowen and Company 34th Annual Healthcare Conference 26th Annual ROTH Conference AmpliPhi BioSciences Corporation (OTCBB: APHB), the leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant infections, announced that President and CEO, Philip Young will be presenting at the Cowen and Company 34^th Annual Healthcare Conference at the Boston Marriott […]
Link to press release here.
7 January 2014: Analysis from leading healthcare fund manager BioScience Managers has highlighted the outstanding year for biotech stocks on the ASX in 2013 with an average gain of 53.6%* across the sector. These findings compare with the All Ordinaries index that increased by 14.7% over 2013 and theS&P/ASX 200 Health Care Index which increased 23.5% […]
ASX announcement here.
Link to press release here. RICHMOND, VA, US, COLWORTH, UK and SYDNEY, AUSTRALIA, December, 16 2013 – AmpliPhi BioSciences Corporation (OTCBB: APHB), the global leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant infections, announced today that it has entered into a definitive stock purchase agreement to raise approximately $18 million in a […]
ASX announcement link here. Avita CFO Mr Tim Rooney appointed interim CEO following resignation of Managing Director and CEO William Dolphin. Ian MacPherson elected as interim board Chairman following resignation of Dalton Gooding as Chairman. Internal progress made to review company remuneration report.